Step's wholly-owned subsidiary is supported by national project approval!
-
Last Update: 2020-01-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, Shandong step Pharmaceutical Co., Ltd announced that Shandong step Shenzhou Pharmaceutical Co., Ltd., a wholly-owned subsidiary of step pharmaceutical, has recently received the notice on the project approval of 2019 annual implementation plan of major new drug creation and technology major projects issued by the Research Center for medical and health science and technology development of the national health and Health Commission (h.k.h [2019] no.764) The project "research and development of new varieties of innovative antibody drugs and construction of key innovative technology system" (Project No.: 2019zx0973201) participated by him was supported The specific contents are as follows: project responsible unit: the Fourth Military Medical University of the Chinese people's Liberation Army Main participants: Shanghai Junshi Biomedical Technology Co., Ltd., Xinda biopharmaceutical (Suzhou) Co., Ltd., Jiangsu Pacific Minogue biopharmaceutical Co., Ltd., Baiji Shenzhou (Shanghai) Biotechnology Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Kangning Jierui Biotechnology Co., Ltd., Zhongshan kangfang biomedical Co., Ltd., Shandong Province Project implementation period: from January 2019 to December 2020: total fund: 424.8792 million yuan, including 9 central financial funds, 2.821 million yuan, 9.281 million yuan in 2019 and 0 million yuan in 2020 The main research content of this project is to establish innovative antibody drug discovery and preparation, drug resistance evaluation, clinical and transformation research, industrialization and other innovative antibody drugs and their key technology systems, with the development of new varieties of innovative antibody drugs as the main line There are 20 innovative projects in the project, and 3 cutting-edge key technologies will be generated through innovative varieties Through the implementation of this project, the project team will develop a number of innovative antibody drugs, improve the technical level of domestic high-end biopharmaceutical industry, and improve the quality level and standard of antibody products in China Adorable adorable
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
